How I Treat

Siponimod is a second-generation oral sphingosine 1-phosphate (S1P) receptor modulator that was approved by the US Food and Drug Administration (FDA) in March 2019 for the treatment of relapsing types of multiple sclerosis (MS), including “active” secondary progressive MS (SPMS).1 The phenotypic subtypes of MS are defined by their clinical course.2 Most patients initially exhibit…